Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 in relapsed or refractory mantle cell lymphoma
NCT06106841Phase 2Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in mantle cell lymphoma (MCL), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Oct 2023; status: terminated.
02
Drugs
TQB3909
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06106841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106841.